Back to Menu
Basis for Medullary Thyroid Carcinoma Diagnosis
1.Serum calcitonin testing
The most characteristic blood biomarker. Markedly elevated levels suggest MTC and are used for screening, diagnosis, and postoperative surveillance.
2.Carcinoembryonic antigen testing
An important tumor marker that should be measured alongside calcitonin; its level reflects tumor burden and disease progression.
3.High-resolution thyroid ultrasonography
The first-line imaging modality. MTC often appears as a solid hypoechoic nodule with microcalcifications; ultrasonography also assesses cervical lymph nodes.
4.Ultrasound-guided fine-needle aspiration biopsy
A key step for preoperative confirmation. Diagnostic accuracy can be improved by combining cell-block preparation with calcitonin immunohistochemistry.
5.Preoperative imaging for staging
Contrast-enhanced cervical CT and chest CT are used to evaluate local invasion, lymph node involvement, and distant metastasis.
6.RET mutation testing
All patients should undergo germline RET testing to distinguish sporadic from hereditary disease and to guide family screening.
7.Screening for multiple endocrine neoplasia–associated conditions
In hereditary cases, evaluation for pheochromocytoma and hyperparathyroidism is required; pheochromocytoma must be excluded preoperatively to ensure surgical safety.
8.Postoperative pathological diagnosis and staging
The gold standard. Immunohistochemistry confirms diagnosis, and pTNM staging guides subsequent management and prognostic assessment.
9.Daily self-check for medullary thyroid carcinoma
Monthly mirror-based observation of the neck and palpation for swallowing-related mobile masses are recommended, although regular ultrasonography is more important.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that delayed diagnosis of medullary thyroid carcinoma can lead to extensive invasion and metastasis, threatening life. Early and accurate diagnosis is the foundation of effective treatment. A systematic approach is essential: serum biomarkers serve as diagnostic clues, pathology provides definitive confirmation, and genetic testing establishes the clinical context. This framework guides curative surgery and targeted therapy, ultimately improving survival outcomes and preserving the dignity of life.
Basis for Medullary Thyroid Carcinoma Diagnosis
1.Serum calcitonin testing
The most characteristic blood biomarker. Markedly elevated levels suggest MTC and are used for screening, diagnosis, and postoperative surveillance.
2.Carcinoembryonic antigen testing
An important tumor marker that should be measured alongside calcitonin; its level reflects tumor burden and disease progression.
3.High-resolution thyroid ultrasonography
The first-line imaging modality. MTC often appears as a solid hypoechoic nodule with microcalcifications; ultrasonography also assesses cervical lymph nodes.
4.Ultrasound-guided fine-needle aspiration biopsy
A key step for preoperative confirmation. Diagnostic accuracy can be improved by combining cell-block preparation with calcitonin immunohistochemistry.
5.Preoperative imaging for staging
Contrast-enhanced cervical CT and chest CT are used to evaluate local invasion, lymph node involvement, and distant metastasis.
6.RET mutation testing
All patients should undergo germline RET testing to distinguish sporadic from hereditary disease and to guide family screening.
7.Screening for multiple endocrine neoplasia–associated conditions
In hereditary cases, evaluation for pheochromocytoma and hyperparathyroidism is required; pheochromocytoma must be excluded preoperatively to ensure surgical safety.
8.Postoperative pathological diagnosis and staging
The gold standard. Immunohistochemistry confirms diagnosis, and pTNM staging guides subsequent management and prognostic assessment.
9.Daily self-check for medullary thyroid carcinoma
Monthly mirror-based observation of the neck and palpation for swallowing-related mobile masses are recommended, although regular ultrasonography is more important.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that delayed diagnosis of medullary thyroid carcinoma can lead to extensive invasion and metastasis, threatening life. Early and accurate diagnosis is the foundation of effective treatment. A systematic approach is essential: serum biomarkers serve as diagnostic clues, pathology provides definitive confirmation, and genetic testing establishes the clinical context. This framework guides curative surgery and targeted therapy, ultimately improving survival outcomes and preserving the dignity of life.